Ovid Therapeutics Faces Going Concern Doubt Amidst Widening Losses

Ticker: OVID · Form: 10-Q · Filed: 2025-08-13T00:00:00.000Z

Sentiment: bearish

Topics: Biotechnology, Going Concern, Net Loss, Nasdaq Compliance, Liquidity Risk, Biopharmaceutical, Strategic Alternatives

Related Tickers: OVID

TL;DR

**OVID is bleeding cash and explicitly warns it might not survive the next year, making it a high-risk bet for any investor.**

AI Summary

Ovid Therapeutics Inc. reported a net loss of $4.7 million for the three months ended June 30, 2025, a significant decline from the net income of $8.5 million in the same period of 2024. For the six months ended June 30, 2025, the net loss was $14.9 million, compared to a net loss of $3.2 million in the prior year. Revenue saw a substantial increase, reaching $6.3 million for the three months ended June 30, 2025, up from $0.2 million in 2024, primarily driven by license and other revenue. However, operating expenses decreased, with Research and Development falling to $6.5 million from $12.6 million, and General and Administrative expenses dropping to $4.9 million from $8.1 million for the three-month period. The company's cash, cash equivalents, and marketable securities stood at $38.3 million as of June 30, 2025, but management believes this will not be sufficient to fund operations for the next 12 months. Ovid faces substantial doubt about its ability to continue as a going concern, evidenced by an accumulated deficit of $319.2 million and negative operating cash flows of $15.1 million for the six months ended June 30, 2025. The company is actively evaluating strategic alternatives, including additional financings or partnerships, and recently transferred its common stock listing to the Nasdaq Capital Market to regain compliance with Nasdaq's minimum bid price requirement.

Why It Matters

Ovid's significant net losses and explicit 'going concern' warning signal deep financial distress, directly impacting investor confidence and potentially leading to further stock price depreciation. For employees, this raises concerns about job security and the company's long-term viability. Customers and the broader market could see delays or abandonment of promising drug candidates if Ovid cannot secure additional funding, hindering advancements in brain condition treatments. In a competitive biopharmaceutical landscape, Ovid's struggle to maintain liquidity and Nasdaq compliance puts it at a severe disadvantage against better-capitalized rivals, making it difficult to attract talent or secure partnerships.

Risk Assessment

Risk Level: high — Ovid Therapeutics explicitly states 'substantial doubt about the Company's ability to continue as a going concern' in Note 1. This is supported by an accumulated deficit of $319.2 million as of June 30, 2025, and net cash used in operating activities of $15.1 million for the six months ended June 30, 2025. Furthermore, management believes existing cash, cash equivalents, and marketable securities of $38.3 million will not fund operations for the next 12 months.

Analyst Insight

Investors should exercise extreme caution and consider divesting OVID shares due to the explicit 'going concern' warning and significant financial instability. Monitor closely for any successful capital raises or strategic partnerships, but be aware that failure to secure funding could lead to further dilution or even bankruptcy.

Financial Highlights

debt To Equity
0.39
revenue
$6,272,000
operating Margin
-81.09%
total Assets
$77,428,000
total Debt
$21,639,000
net Income
($4,684,000)
eps
($0.06)
gross Margin
N/A
cash Position
$38,347,000
revenue Growth
3600%

Revenue Breakdown

SegmentRevenueGrowth
License and other revenue$6,272,0003600%

Key Numbers

Key Players & Entities

FAQ

What is Ovid Therapeutics' current financial liquidity position?

As of June 30, 2025, Ovid Therapeutics Inc. had $38.3 million in cash, cash equivalents, and marketable securities. However, management believes this amount will not be sufficient to fund its current operating plans through the next 12 months.

Why is Ovid Therapeutics facing a 'going concern' warning?

Ovid Therapeutics is facing a 'going concern' warning due to recurring losses, negative operating cash flows, an accumulated deficit of $319.2 million as of June 30, 2025, and management's belief that existing cash will not cover operations for the next 12 months.

How did Ovid Therapeutics' revenue change in the last quarter?

For the three months ended June 30, 2025, Ovid Therapeutics' total revenue significantly increased to $6.272 million, up from $0.169 million in the same period of 2024, primarily driven by license and other revenue.

What are Ovid Therapeutics' plans to address its financial challenges?

Ovid Therapeutics is currently evaluating strategic alternatives, including additional financings through equity offerings or debt, collaborations, strategic alliances, or licensing agreements to secure additional capital and fund its operations.

What is the status of Ovid Therapeutics' Nasdaq listing compliance?

Ovid Therapeutics received a notification on February 10, 2025, regarding its common stock bid price falling below $1.00. On August 12, 2025, the company received approval to transfer its listing from the Nasdaq Global Select Market to the Nasdaq Capital Market to regain compliance.

How much did Ovid Therapeutics spend on research and development?

For the three months ended June 30, 2025, Ovid Therapeutics spent $6.465 million on research and development, a decrease from $12.582 million in the same period of 2024.

What are the primary risks for Ovid Therapeutics investors?

Primary risks for Ovid Therapeutics investors include the substantial doubt about its ability to continue as a going concern, the need for significant additional capital, the inherent uncertainties of pharmaceutical product development, and the challenges of protecting intellectual property rights.

What is Ovid Therapeutics' accumulated deficit as of June 30, 2025?

As of June 30, 2025, Ovid Therapeutics Inc. reported an accumulated deficit of $319.2 million, reflecting the cumulative losses incurred since its inception.

What kind of company is Ovid Therapeutics?

Ovid Therapeutics Inc. is a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet medical needs. It was incorporated in Delaware on April 1, 2014.

How many shares of common stock does Ovid Therapeutics have outstanding?

As of August 8, 2025, Ovid Therapeutics Inc. had 71,109,514 shares of common stock, $0.001 par value per share, outstanding.

Risk Factors

Industry Context

Ovid Therapeutics operates in the biopharmaceutical sector, a highly competitive and capital-intensive industry. The company focuses on developing novel medicines for rare neurological diseases. Success hinges on significant R&D investment, clinical trial outcomes, and securing partnerships or funding to advance drug candidates through regulatory approval.

Regulatory Implications

Ovid's recent transfer to the Nasdaq Capital Market highlights the importance of maintaining exchange listing requirements, particularly minimum bid price. Failure to comply could lead to delisting, severely impacting liquidity and investor confidence. Ongoing clinical trial progress and FDA approvals are also critical regulatory hurdles.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Accumulated deficit
The cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates Ovid's history of unprofitability, with a significant deficit of $319.2 million as of June 30, 2025.)
Going concern
A business's ability to continue operating for the foreseeable future without the threat of liquidation. (Management has expressed substantial doubt about Ovid's ability to continue as a going concern due to insufficient cash for the next 12 months.)
Marketable securities
Investments that are readily convertible to cash, such as stocks and bonds. (A component of Ovid's liquid assets, which decreased significantly from $26.8 million to $9.9 million during the first half of 2025.)
Right-of-use asset, net
An asset representing the right to use a leased asset over the lease term, recognized under lease accounting standards. (Represents Ovid's long-term lease obligations, with a net value of $12.2 million as of June 30, 2025.)
Deferred revenue
Revenue that has been received by a company but not yet earned. (Ovid reported $718,000 in deferred revenue as of June 30, 2025, indicating payments received for services or licenses not yet fully recognized.)

Year-Over-Year Comparison

Compared to the prior year's second quarter, Ovid Therapeutics has seen a dramatic shift from net income of $8.5 million to a net loss of $4.7 million. While total revenue surged from $0.2 million to $6.3 million, primarily from licensing, this was overshadowed by a significant increase in net loss for the six-month period from $3.2 million to $14.9 million. Operating expenses have been reduced, with R&D and G&A expenses decreasing substantially year-over-year, but the company faces significant financial headwinds, including a substantial accumulated deficit and insufficient cash for the next 12 months, leading to going concern doubts.

Filing Stats: 4,558 words · 18 min read · ~15 pages · Grade level 18.6 · Accepted 2025-08-13 08:03:46

Key Financial Figures

Filing Documents

Financial Statements (Unaudited)

Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 33 Item 4.

Controls and Procedures

Controls and Procedures 33 PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 34 Item 1A.

Risk Factors

Risk Factors 34 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 69 Item 5. Other Information 69 Item 6. Exhibits 70

Signatures

Signatures Table of Contents SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical fact are "forward-looking statements" for purposes of this Quarterly Report on Form 10-Q. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "project," "should," "target," "will," "would" or the negative or plural of those terms, and similar expressions.

Forward-looking statements include, but are not limited to, statements about

Forward-looking statements include, but are not limited to, statements about: our ability to identify additional novel compounds with significant commercial potential to acquire or in-license; our ability to successfully acquire or in-license additional drug candidates on reasonable terms; the potential use, development and therapeutic potential of the drug candidates in our pipeline; our ability to develop medical therapies that deliver preferable safety and tolerability profiles to approved drugs; our expectations regarding the duration of our cash runway and the expectation that it will support our operations and development programs; our estimates regarding expenses, future revenue including any royalty or milestone payments, capital requirements and needs for additional financing; our ability to obtain regulatory approval of our current and future drug candidates; our expectations regarding the timing of initiation, completion, and results and data from clinical trials and potential regulatory filings; our expectations regarding the potential market size for drug candidates and the rate and degree of market acceptance of such drug candidates; our ability to fund our working capital requirements; the implementation of our business model and strategic plans for our business and drug candidates, including the programs in our planned pipeline; developments or disputes concerning our intellectual property or other proprietary rights; our ability to maintain and establish collaborations or obtain additional funding; our expectations regarding government and third-party payor coverage and reimbursement; our ability to compete in the markets we serve; the impact of government laws and regulations; developments relating to our competitors and our industry; interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. OVID THERAPEUTICS INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) June 30, 2025 December 31, 2024 Assets (unaudited) Current assets: Cash and cash equivalents $ 28,415 $ 26,301 Marketable securities 9,932 26,774 Prepaid expenses and other current assets 3,742 2,865 Total current assets 42,089 55,940 Long-term equity investments 20,908 20,974 Restricted cash 1,931 1,931 Right-of-use asset, net 12,215 12,797 Property and equipment, net 285 433 Other noncurrent assets — 92 Total assets $ 77,428 $ 92,167 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 3,950 $ 3,192 Accrued expenses 2,872 5,994 Current portion, lease liability 1,384 1,336 Deferred revenue 718 — Total current liabilities 8,924 10,522 Long-term liabilities: Lease liability 12,715 13,419 Total liabilities 21,639 23,941 Stockholders' equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at June 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 125,000,000 shares authorized; 71,109,514 and 71,009,866 shares issued and outstanding at June 30, 2025 and December 31, 2024, respectively 71 71 Additional paid-in-capital 375,005 372,489 Accumulated other comprehensive loss ( 69 ) ( 35 ) Accumulated deficit ( 319,218 ) ( 304,299 ) Total stockholders ' equity 55,789 68,226 Total liabilities and stockholders ' equity $ 77,428 $ 92,167 See accompanying notes to these unaudited condensed consolidated financial statements 3 Table of Contents OVID THERAPEUTICS INC. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share data) For The Three Months Ended June 30, 2025 For The Three Months Ended June 30, 2024 For The Six Months Ended June 30, 2025 For The Six Months Ended June 30, 2024

View on Read The Filing